Related Experiment Video

Updated: Sep 10, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K

Hemoglobin and High-Density Lipoprotein as Biomarker of Left Atrial Dilatation in Sickle Cell Disease

Guillaume Feugray1, Maximilien Grall2, Baptiste Gillardin3

  • 1Department of General Biochemistry, Normandie University, UNIROUEN, INSERM U1096 EnVI CHU Rouen Rouen France.

Ejhaem
|August 27, 2025
PubMed

Insights

Sickle cell disease (SCD) patients often have cardiac remodeling. Biomarkers like hemoglobin and HDL-C can predict left atrial enlargement, aiding early detection of heart issues in SCD.

Area of Science:

  • Cardiology
  • Hematology
  • Biomarkers

Background:

  • Sickle cell disease (SCD) is linked to cardiac remodeling, especially left atrial dilatation, a predictor of poor cardiovascular outcomes.
  • Echocardiography is crucial for assessing cardiac abnormalities in SCD patients.

Discussion:

  • Left atrial dilatation affects 61% of adult SCD patients.
  • Dilatation is significantly associated with hemoglobin levels, hemoglobin S, HDL-C, and the atherogenic index of plasma.
  • An algorithm combining low hemoglobin (≤ 9.7 g/dL) and low HDL-C (≤ 50 mg/dL) demonstrated high diagnostic accuracy.

Key Insights:

  • Biomarker-based screening can identify SCD patients at risk for left atrial remodeling.
  • Early detection of cardiac complications in SCD is feasible through targeted biomarker assessment.

Outlook:

  • This approach is particularly valuable in resource-limited settings for proactive cardiovascular care in SCD.
  • Further research can refine predictive algorithms for comprehensive SCD cardiac risk stratification.

Keywords:
hemolysishigh‐density lipoproteinleft atrial remodelingsickle cell disease

More Related Videos

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

9.9K
Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics07:42

Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics

Published on: February 19, 2017

8.9K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
213
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
334
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
47
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
34.8K
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
52